- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07941622
Study of Hexaxim Compared With Pentaxim Administered With a Monovalent Hepatitis B Vaccine in Healthy Chinese Infants.
A Nested Phase 3, Randomized, Active-controlled, Open-label, 2-arm, Multicenter Study to Investigate the Immunogenicity and Safety of Sanofi's Hexavalent DTaP-IPV-HB-PRP~T Combined Vaccine Given at 2, 4, and 6 Months of Age Compared With DTaP-IPV//PRP~T Combined Vaccine (Pentaxim™) Given at 2, 4, and 6 Months of Age Administered With a Monovalent Hepatitis B Vaccine Given at 1 and 6 Months of Age to Healthy Chinese Infants Who Previously Received a Birth Dose of Monovalent Hepatitis B Vaccine
The purpose of this study is to measure the safety and immunogenicity of Hexaxim given at 2, 4, and 6 MoA compared with Pentaxim given at 2, 4, and 6 MoA plus a monovalent Hep B vaccine given at 1 and 6 MoA in healthy Chinese infants born to HBsAg seronegative mothers.
Study details include:
- The study duration per participant will be approximately 18 months.
- The study vaccines administration:
- Group 1: for the primary series vaccination, Hexaxim will be administered 3 doses at 2, 4, and 6 MoA.
- Group 2: for the primary series vaccination, Pentaxim will be administered 3 doses at 2, 4, and 6 MoA, and the monovalent Hep B vaccine will be administered at 1 and 6 MoA.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Trial Transparency email recommended (Toll free for US & Canada)
- Telefoonnummer: option 6 800-633-1610
- E-mail: Contact-US@sanofi.com
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Aged 30 to 45 days on the day of inclusion, and have received 1 dose of monovalent Hep B vaccine
- Born at full term of pregnancy (≥37 weeks) and with a birth weight ≥2.5 kg or born after a gestation period above 28 (>28 weeks) through 36 weeks with a birth weight ≥1.5 kg, and in both cases medically stable as assessed by the investigator
- Participants who are born to mothers with documented HBsAg seronegative status
- Informed consent form has been signed and dated by the parent(s) or other LAR
- Participant and parent/LAR are able to attend all scheduled visits and to comply with all study procedures
Exclusion Criteria:
- Known/suspected immunodeficiency; immunosuppressive therapy since birth; long-term systemic corticosteroid therapy
- History of diagnosis of Hepatitis B, diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b infection
- History of seizure or significant stable or progressive neurological disorders
- Known systemic hypersensitivity to any study intervention components, or history of a life-threatening reaction to study interventions or product with the same substances
- Known thrombocytopenia
- Bleeding disorder
- Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
- Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (axillary temperature ≥37.5°C) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
- Any vaccine given since birth or planned receipt of any vaccine until 1 month after the completion of the primary series vaccination with the study interventions except for Bacille Calmette-Guérin (BCG) vaccine and meningococcal polysaccharide vaccine-A.
- Previous vaccination against D, T, pertussis, poliomyelitis, Hep B (except the dose of Hep B given at birth) or Haemophilus influenzae type b infections (since birth) with an investigational or marketed vaccine.
- Receipt of immune globulins, blood or blood-derived products
- Participation in another clinical study for a vaccine, drug, medical device, or medical procedure at the time of study enrollment or planned participation during the present study period.
- Known personal or maternal history of HIV or HCV seropositivity
- Being in an emergency setting
- Identified as a natural or adopted child of the Investigator/study site employee with direct involvement in the study
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Group 1 (the investigational group)
Hexaxim at 2, 4 and 6 MoA |
Pharmaceutical form:Suspension for injection in a pre-filled syringe Route of administration:IM injection |
|
Actieve vergelijker: Group 2 (the comparator group)
Pentaxim at 2, 4, 6, and 18 MoA, and the monovalent Hepatitis B vaccine at 1 and 6 MoA |
Pharmaceutical form:Freeze-dried PRP~T in a vial reconstituted with the injectable suspension of DTaP-IPV in a pre-filled syringe Route of administration:IM injection Pharmaceutical form: Depending on the brand procured Route of administration:IM injection |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
1 month after the last dose of primary series (investigational group [Hexaxim: Group 1] and comparator group [Pentaxim and monovalent Hep B: Group 2]) (7 MoA):
Tijdsspanne: Day181
|
Anti-D Ab concentrations ≥0.1 IU/mL Anti-T Ab concentrations ≥0.1 IU/mL Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil) Anti-PRP Ab concentrations ≥0.15 µg/mL Seroconversion for anti-PT and anti-FHA, defined as anti-PT and anti-FHA ≥4-fold Ab concentrations increase from pre-Dose 1 to 1 month post-Dose 3 Anti-Hep B Ab concentrations ≥10 mIU/mL GMC of PT and FHA |
Day181
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Baseline, pre-vaccination sample
Tijdsspanne: Day 31
|
Ab concentrations/titers for each Ag Ab concentrations/titers above a cut-off:
|
Day 31
|
|
1 month after the last dose of primary series:
Tijdsspanne: Day181
|
Ab concentrations/titers for each Ag Ab concentrations/titers above a cut-off:
|
Day181
|
|
Before the booster dose:
Tijdsspanne: Day 511
|
Ab concentrations/titers for each Ag of Pentaxim and Hep B Ab concentrations/titers above a cut-off:
|
Day 511
|
|
1 month after the booster dose:
Tijdsspanne: Day 541
|
Ab concentrations/titers for each Ag of Pentaxim Ab concentrations/titers above a cut-off:
|
Day 541
|
|
Presence of immediate unsolicited adverse events (AEs)
Tijdsspanne: 30 minutes after each and any vaccination
|
30 minutes after each and any vaccination
|
|
|
Presence of solicited injection site reactions
Tijdsspanne: for 8 days, including the day of each and any vaccination
|
(pre-listed in the participant diary and case report form [CRF]) |
for 8 days, including the day of each and any vaccination
|
|
Presence of solicited systemic reactions
Tijdsspanne: for 8 days, including the day of each and any vaccination
|
(pre-listed in the participant diary and CRF) |
for 8 days, including the day of each and any vaccination
|
|
Presence of unsolicited AEs
Tijdsspanne: for 30 days, including the day of each and any vaccination
|
for 30 days, including the day of each and any vaccination
|
|
|
Presence of serious adverse events (SAEs)
Tijdsspanne: up to 12 months post last dose of vaccination in the primary series, and up to 1 month post booster vaccination
|
up to 12 months post last dose of vaccination in the primary series, and up to 1 month post booster vaccination
|
|
|
Presence of related SAEs and fatal case regardless of causality
Tijdsspanne: Day 541
|
Day 541
|
|
|
Presence of AEs leading to study discontinuation
Tijdsspanne: Day 541
|
Day 541
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- A3L00054
- U1111-1227-3420 (Register-ID: ICTRP)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .